The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), Johnson & Johnson (Gold), BeOne Medicines (Silver) and Lilly (Silver).
The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Emerging treatments for patients with CLL previously exposed to BTK inhibitors and venetoclax
Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the evolving treatment landscape for patients with chronic lymphocytic lymphoma (CLL) who have received prior BTK inhibitor and venetoclax therapy, highlighting the potential of non-covalent BTK inhibitors and degraders as next-line therapies. Dr Davids also discusses the potential of immune-based therapies, including the bispecifics epcoritamab and surovatamig, in earlier lines of therapy. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So I think for patients who have had prior covalent BTK inhibitor and venetoclax, the non-covalent BTK inhibitors like the approved pirtobrutinib and others in development like nemtabrutinib are really a nice option for the next line of therapy. But we’re already seeing actually some very exciting data from BTK degrader drugs as well. And even in patients who have progressed after three lines of therapy covalent and non-covalent BTK inhibitors as well as venetoclax and now they’re responding to BTK degraders so i think that’s a particularly exciting mechanism in CLL immune-based therapy i think is also very interesting we’ve seen some early data with epcoritimab the CD20/CD3 bispecific in CLL where patients like that who are very refractory had about a 40% rate of CR...
So I think for patients who have had prior covalent BTK inhibitor and venetoclax, the non-covalent BTK inhibitors like the approved pirtobrutinib and others in development like nemtabrutinib are really a nice option for the next line of therapy. But we’re already seeing actually some very exciting data from BTK degrader drugs as well. And even in patients who have progressed after three lines of therapy covalent and non-covalent BTK inhibitors as well as venetoclax and now they’re responding to BTK degraders so i think that’s a particularly exciting mechanism in CLL immune-based therapy i think is also very interesting we’ve seen some early data with epcoritimab the CD20/CD3 bispecific in CLL where patients like that who are very refractory had about a 40% rate of CR. There’s a newer drug called suravatamig, which is currently in clinical trials. That’s a CD19/CD3 bispecific that we’re also excited about. And I think if we can move these drugs up into earlier lines of therapy and maybe treat patients who already have debulked disease, we have real potential to get very deep responses and long progression-free survival and potentially even cure a subset of patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
